PDGFRL

Summary

PDGFRL (platelet derived growth factor receptor like, HGNC:8805) is a protein-coding gene on chromosome 8p22, encoding Platelet-derived growth factor receptor-like protein (Q15198).

This gene encodes a protein with significant sequence similarity to the ligand binding domain of platelet-derived growth factor receptor beta. Mutations in this gene, or deletion of a chromosomal segment containing this gene, are associated with sporadic hepatocellular carcinomas, colorectal cancers, and non-small cell lung cancers. This suggests this gene product may function as a tumor suppressor.

Source: NCBI Gene 5157 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 105 total — 2 pathogenic
• Phenotypes (HPO): 11
• MANE Select transcript: NM_001372073

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8805
Approved symbol	PDGFRL
Name	platelet derived growth factor receptor like
Location	8p22
Locus type	gene with protein product
Status	Approved
Aliases	PRLTS
Ensembl gene	ENSG00000104213
Ensembl biotype	protein_coding
OMIM	604584
Entrez	5157

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000251630, ENST00000523248, ENST00000541323, ENST00000673645, ENST00000959618

RefSeq mRNA: 2 — MANE Select: NM_001372073 NM_001372073, NM_006207

CCDS: CCDS6003

Canonical transcript exons

ENST00000251630 — 6 exons

Exon	Start	End
ENSE00000681771	17589468	17589765
ENSE00000681776	17621051	17621202
ENSE00000681782	17628487	17628780
ENSE00000681789	17634074	17634213
ENSE00003896565	17577216	17577307
ENSE00003897004	17642613	17643144

Expression profiles

Bgee: expression breadth ubiquitous, 236 present calls, max score 96.37.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.7473 / max 198.4371, expressed in 1169 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
87549	5.6861	1164
87548	0.0612	22

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pericardium	UBERON:0002407	96.37	gold quality
tendon of biceps brachii	UBERON:0008188	96.15	gold quality
synovial joint	UBERON:0002217	96.14	gold quality
tibial nerve	UBERON:0001323	95.54	gold quality
vena cava	UBERON:0004087	95.30	gold quality
oocyte	CL:0000023	94.32	gold quality
tibia	UBERON:0000979	94.21	gold quality
secondary oocyte	CL:0000655	94.10	gold quality
cartilage tissue	UBERON:0002418	93.79	gold quality
layer of synovial tissue	UBERON:0007616	92.44	gold quality
nipple	UBERON:0002030	92.15	gold quality
left ovary	UBERON:0002119	91.66	gold quality
parietal pleura	UBERON:0002400	91.55	gold quality
calcaneal tendon	UBERON:0003701	91.54	gold quality
upper arm skin	UBERON:0004263	91.17	gold quality
thoracic mammary gland	UBERON:0005200	90.80	gold quality
tendon	UBERON:0000043	90.77	gold quality
right ovary	UBERON:0002118	90.68	gold quality
mammary gland	UBERON:0001911	90.48	gold quality
peritoneum	UBERON:0002358	89.98	gold quality
omental fat pad	UBERON:0010414	89.98	gold quality
saphenous vein	UBERON:0007318	89.91	gold quality
dorsal root ganglion	UBERON:0000044	89.80	gold quality
adipose tissue of abdominal region	UBERON:0007808	89.78	gold quality
ovary	UBERON:0000992	89.24	gold quality
skin of hip	UBERON:0001554	88.97	gold quality
subcutaneous adipose tissue	UBERON:0002190	88.82	gold quality
thyroid gland	UBERON:0002046	88.65	gold quality
periodontal ligament	UBERON:0008266	88.61	gold quality
hindlimb stylopod muscle	UBERON:0004252	88.35	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GATA3

miRNA regulators (miRDB)

31 targeting PDGFRL, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-6744-5P	99.93	66.82	748
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107
HSA-MIR-320D	99.77	69.73	2107
HSA-MIR-4429	99.77	69.62	2111
HSA-MIR-3156-3P	99.76	66.72	939
HSA-MIR-2681-5P	99.75	67.64	1655
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-4643	99.49	67.63	1791
HSA-MIR-6505-3P	99.34	67.39	1071
HSA-MIR-4652-3P	99.33	70.02	2742
HSA-MIR-3160-5P	99.28	69.07	1938
HSA-MIR-4463	98.56	66.05	1071
HSA-MIR-633	98.35	69.45	1167
HSA-MIR-617	96.79	65.96	738

Literature-anchored findings (GeneRIF, showing 3)

• Results indicate that PDGFRL functions as a tumor suppressor, inhibiting the growth of colorectal cancer cells. (PMID:20333786)
• Data indicate the association between SNP rs17633132:C/T in PDGFRL with Behcet disease and suggest that the PDGFRL gene may be involved in Behcet disease by modulating its transcription. (PMID:22926996)
• review elucidates the role of tumor stroma interactions, the roles of PDGF receptor signaling in cancer-associated fibroblasts via alteration of stromal matrix composition and the mitogenic effects of cancer-derived PDGFs. (PMID:23944365)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	pdgfrl	ENSDARG00000006456
mus_musculus	Pdgfrl	ENSMUSG00000031595
rattus_norvegicus	Pdgfrl	ENSRNOG00000010832

Protein

Protein identifiers

Platelet-derived growth factor receptor-like protein — Q15198 (reviewed: Q15198)

Alternative names: PDGF receptor beta-like tumor suppressor

All UniProt accessions (2): A0A669KBD1, Q15198

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Forms a complex composed of PDGFRL, TNK2 and GRB2.

Subcellular location. Secreted.

Tissue specificity. Expressed in colon, lung and liver.

Disease relevance. Colorectal cancer (CRC) [MIM:114500] A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. The gene represented in this entry is involved in disease pathogenesis. A polymorphism in PDGFRL has been reported to be associated with susceptibility to Behcet disease. Behcet disease is a complex multiple-system disorder characterized by recurrent oral ulcerations, recurrent genital ulcerations, typical skin lesions, and uveitis. Behcet disease also involves joints, blood vessels, musculoskeletal, neurological systems, and the gastrointestinal tract.

RefSeq proteins (2): NP_001359002, NP_006198 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR042495	PDGFRL	Family

Pfam: PF13927, PF21339

UniProt features (12 total): domain 2, glycosylation site 2, disulfide bond 2, signal peptide 1, chain 1, sequence variant 1, sequence conflict 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15198-F1	83.54	0.73

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 96–143, 293–357

Glycosylation sites (2): 132, 219

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 194 (showing top): GOBP_PLATELET_DERIVED_GROWTH_FACTOR_RECEPTOR_SIGNALING_PATHWAY, MODULE_64, GOZGIT_ESR1_TARGETS_DN, GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP, KYNG_DNA_DAMAGE_DN, KYNG_DNA_DAMAGE_BY_4NQO, SENESE_HDAC1_AND_HDAC2_TARGETS_DN, BROWNE_HCMV_INFECTION_48HR_DN, BOQUEST_STEM_CELL_CULTURED_VS_FRESH_DN, ROZANOV_MMP14_TARGETS_UP, GOBP_RESPONSE_TO_PLATELET_DERIVED_GROWTH_FACTOR, MODULE_99, CORRE_MULTIPLE_MYELOMA_UP, ONDER_CDH1_TARGETS_2_UP, MODULE_259

GO Biological Process (4): G protein-coupled receptor signaling pathway (GO:0007186), platelet-derived growth factor receptor-beta signaling pathway (GO:0035791), cellular response to platelet-derived growth factor stimulus (GO:0036120), platelet-derived growth factor receptor signaling pathway (GO:0048008)

GO Molecular Function (3): platelet activating factor receptor activity (GO:0004992), platelet-derived growth factor beta-receptor activity (GO:0005019), platelet-derived growth factor receptor activity (GO:0005017)

GO Cellular Component (1): extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
G protein-coupled receptor activity	2
platelet-derived growth factor receptor signaling pathway	2
signal transduction	1
response to platelet-derived growth factor	1
cellular response to growth factor stimulus	1
cell surface receptor protein tyrosine kinase signaling pathway	1
platelet-derived growth factor receptor activity	1
platelet-derived growth factor receptor-beta signaling pathway	1
transmembrane receptor protein tyrosine kinase activity	1
cellular response to platelet-derived growth factor stimulus	1
platelet-derived growth factor binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1050 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PDGFRL	TUSC3	Q13454	962
PDGFRL	PDGFC	Q9NRA1	559
PDGFRL	ERAL1	O75616	432
PDGFRL	SCOC	Q9UIL1	412
PDGFRL	PDGFD	Q9GZP0	370
PDGFRL	LARS2	Q15031	370
PDGFRL	HSD17B4	P51659	368
PDGFRL	FLT4	P35916	364
PDGFRL	ZC2HC1C	Q53FD0	364
PDGFRL	TWNK	Q96RR1	354
PDGFRL	GABARAPL2	P60520	353
PDGFRL	HTR3B	O95264	353
PDGFRL	CHRNA6	Q15825	353
PDGFRL	SCRIB	Q14160	353
PDGFRL	NRP2	O60462	353
PDGFRL	F7	P08709	353

IntAct

38 interactions, top by confidence:

A	B	Type	Score
ACTR1A	DCTN2	psi-mi:“MI:0914”(association)	0.790
PDGFRL	ANKRD28	psi-mi:“MI:0914”(association)	0.530
SGSM1	CETN2	psi-mi:“MI:0914”(association)	0.530
TNFSF8	LGALS8	psi-mi:“MI:0914”(association)	0.530
PDGFRL	HS3ST1	psi-mi:“MI:0915”(physical association)	0.400
PDGFRL	ASPH	psi-mi:“MI:0915”(physical association)	0.370
MAPK12	PDGFRL	psi-mi:“MI:0915”(physical association)	0.370
PDGFRL	MBP	psi-mi:“MI:0915”(physical association)	0.370
PDGFRL	PFKM	psi-mi:“MI:0915”(physical association)	0.370
RANGAP1	PDGFRL	psi-mi:“MI:0915”(physical association)	0.370
SPARCL1	PDGFRL	psi-mi:“MI:0915”(physical association)	0.370
TMEM129	PDGFRL	psi-mi:“MI:0915”(physical association)	0.370
BAAT	PDGFRL	psi-mi:“MI:0915”(physical association)	0.370
CTSV	PDGFRL	psi-mi:“MI:0915”(physical association)	0.370
PDGFRL	FANCC	psi-mi:“MI:0915”(physical association)	0.370
PDGFRL	FBP2	psi-mi:“MI:0915”(physical association)	0.370
PDGFRL	HRAS	psi-mi:“MI:0915”(physical association)	0.370
CCDC180	PDGFRL	psi-mi:“MI:0915”(physical association)	0.370
MAP2K1	PDGFRL	psi-mi:“MI:0915”(physical association)	0.370
PDGFRL	MAPKAPK3	psi-mi:“MI:0915”(physical association)	0.370
PDGFRL	NANS	psi-mi:“MI:0915”(physical association)	0.370
PDGFRL	PPP2CB	psi-mi:“MI:0915”(physical association)	0.370
PPP3R2	PDGFRL	psi-mi:“MI:0915”(physical association)	0.370
SFRP4	PDGFRL	psi-mi:“MI:0915”(physical association)	0.370
PDGFRL	SMAD1	psi-mi:“MI:0915”(physical association)	0.370
TBC1D2	PDGFRL	psi-mi:“MI:0915”(physical association)	0.370
PDGFRL	TGFB1	psi-mi:“MI:0915”(physical association)	0.370
XPA	PDGFRL	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (41): BAAT (Two-hybrid), CTSV (Two-hybrid), FANCC (Two-hybrid), FBP2 (Two-hybrid), HRAS (Two-hybrid), CCDC180 (Two-hybrid), MAP2K1 (Two-hybrid), MAPK3 (Two-hybrid), NANS (Two-hybrid), PPP2CB (Two-hybrid), PPP3R2 (Two-hybrid), SFRP4 (Two-hybrid), SMAD1 (Two-hybrid), TBC1D2 (Two-hybrid), TGFB1 (Two-hybrid)

ESM2 similar proteins: A0A0R4IGV4, A0A8M2B818, B0JYH6, F1LW30, O35112, O46634, O46651, P0C673, P17948, P26453, P35969, P42292, P53767, Q08DK1, Q13740, Q15198, Q1WIM2, Q2PFX1, Q504C1, Q58EG3, Q5DX21, Q5FWR8, Q5R412, Q5RJP7, Q5U2P2, Q5VJ70, Q61490, Q6DJ83, Q6PE55, Q6UXZ4, Q6X936, Q7T2Z5, Q7TSN7, Q80W68, Q8BLQ9, Q8BR86, Q8IZU9, Q8K1S2, Q8N3J6, Q8QHL3

Diamond homologs: Q15198, Q2PFX1, Q5BIP2, Q5RJP7, Q6PE55, Q05030

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 42 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
MAPK cascade	6	24.2×	8e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

105 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	82
Likely benign	3
Benign	2

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
5468	NM_001372073.1(PDGFRL):c.67C>T (p.His23Tyr)	Pathogenic
5469	PDGRL, 2-BP DEL	Pathogenic

SpliceAI

1092 predictions. Top by Δscore:

Variant	Effect	Δscore
8:17589457:A:AG	acceptor_gain	1.0000
8:17589458:C:CA	acceptor_gain	1.0000
8:17589458:C:G	acceptor_gain	1.0000
8:17589464:GCAGT:G	acceptor_loss	1.0000
8:17589465:CA:C	acceptor_loss	1.0000
8:17589466:A:AG	acceptor_gain	1.0000
8:17589466:A:T	acceptor_loss	1.0000
8:17589467:G:GG	acceptor_gain	1.0000
8:17589467:GT:G	acceptor_gain	1.0000
8:17589467:GTT:G	acceptor_gain	1.0000
8:17589467:GTTA:G	acceptor_gain	1.0000
8:17589762:TCAGG:T	donor_loss	1.0000
8:17589764:AGGT:A	donor_loss	1.0000
8:17589765:GGT:G	donor_loss	1.0000
8:17589766:G:GG	donor_gain	1.0000
8:17589766:GTAA:G	donor_loss	1.0000
8:17589767:T:A	donor_loss	1.0000
8:17621049:A:AG	acceptor_gain	1.0000
8:17621050:G:GG	acceptor_gain	1.0000
8:17621050:GC:G	acceptor_gain	1.0000
8:17634072:A:AG	acceptor_gain	1.0000
8:17634073:G:GG	acceptor_gain	1.0000
8:17634210:GAAG:G	donor_gain	1.0000
8:17634211:AAGG:A	donor_loss	1.0000
8:17634214:G:GA	donor_loss	1.0000
8:17634214:G:GG	donor_gain	1.0000
8:17634215:T:G	donor_loss	1.0000
8:17589457:AC:A	acceptor_gain	0.9900
8:17589463:T:A	acceptor_gain	0.9900
8:17589467:GTTAC:G	acceptor_gain	0.9900

AlphaMissense

2443 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:17628502:T:G	F174C	0.999
8:17589698:T:A	C96S	0.997
8:17589699:G:C	C96S	0.997
8:17628562:T:A	V194D	0.997
8:17628567:T:C	C196R	0.997
8:17628568:G:A	C196Y	0.997
8:17628717:T:A	C246S	0.997
8:17628718:G:A	C246Y	0.997
8:17628718:G:C	C246S	0.997
8:17628719:C:G	C246W	0.997
8:17589721:G:C	W103C	0.996
8:17589721:G:T	W103C	0.996
8:17621126:C:G	C143W	0.996
8:17628567:T:A	C196S	0.996
8:17628568:G:C	C196S	0.996
8:17628717:T:C	C246R	0.996
8:17589698:T:C	C96R	0.995
8:17589719:T:A	W103R	0.995
8:17589719:T:C	W103R	0.995
8:17621125:G:A	C143Y	0.995
8:17634151:T:A	C293S	0.995
8:17634151:T:C	C293R	0.995
8:17634152:G:C	C293S	0.995
8:17634193:T:A	W307R	0.995
8:17634193:T:C	W307R	0.995
8:17642744:C:G	C357W	0.995
8:17589693:T:C	L94P	0.994
8:17589699:G:A	C96Y	0.994
8:17621124:T:C	C143R	0.994
8:17628569:T:G	C196W	0.994

dbSNP variants (sampled 300 via entrez): RS1000002260 (8:17594664 C>T), RS1000028112 (8:17619583 C>T), RS1000110290 (8:17618456 T>C), RS1000255244 (8:17603466 C>G,T), RS1000349014 (8:17603694 T>C), RS1000396242 (8:17639922 G>C), RS1000411330 (8:17604888 T>C,G), RS1000507858 (8:17587845 G>A,C), RS1000515568 (8:17615324 G>A), RS1000522177 (8:17591542 G>A,T), RS1000535326 (8:17619757 A>C,G), RS1000542286 (8:17642945 A>G,T), RS1000553400 (8:17616537 T>C), RS1000593482 (8:17590808 A>T), RS1000655611 (8:17576092 T>C)

Disease associations

OMIM: gene MIM:604584 | disease phenotypes: MIM:114550

GenCC curated gene-disease

Mondo (2): colon carcinoma (MONDO:0002032), hepatocellular carcinoma (MONDO:0007256)

Orphanet (1): Hepatocellular carcinoma (Orphanet:88673)

HPO phenotypes

11 total (11 of 11 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0001402	Hepatocellular carcinoma
HP:0001413	Micronodular cirrhosis
HP:0001442	Typified by somatic mosaicism
HP:0002891	Uterine leiomyosarcoma
HP:0003003	Colon cancer
HP:0005584	Renal cell carcinoma
HP:0006572	Subacute progressive viral hepatitis
HP:0006716	Hereditary nonpolyposis colorectal carcinoma
HP:0006740	Transitional cell carcinoma of the bladder
HP:0006753	Neoplasm of the stomach

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST002337_134	Amyotrophic lateral sclerosis (sporadic)	6.000000e-06
GCST005844_7	Placental abruption	5.000000e-06
GCST006431_22	Plasma parathyroid hormone levels	5.000000e-06
GCST007004_2	Hippocampal volume in normal cognition	5.000000e-09
GCST007382_19	Plasma free amino acid levels (adjusted for twenty other PFAAs)	2.000000e-08
GCST007382_5	Plasma free amino acid levels (adjusted for twenty other PFAAs)	3.000000e-08
GCST008865_4	Sphingomyelin 24:0 levels	6.000000e-07
GCST009307_5	Spatial memory	8.000000e-07

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0005035	hippocampal volume
EFO:0005134	amino acid measurement
EFO:0009776	ornithine measurement
EFO:0006524	L-arginine measurement
EFO:0010118	sphingomyelin measurement
EFO:0004874	memory performance

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D006528	Carcinoma, Hepatocellular	C04.557.470.200.025.255; C04.588.274.623.160; C06.301.623.160; C06.552.697.160

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

56 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	5
Benzo(a)pyrene	decreases expression, increases methylation	4
sodium arsenite	affects methylation, decreases expression, increases expression	3
bisphenol A	increases expression, increases methylation	2
Air Pollutants	increases abundance, decreases expression	2
Dexamethasone	increases expression, decreases expression, affects cotreatment	2
Estradiol	decreases expression, increases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
Cyclosporine	decreases expression, increases expression	2
Cadmium Chloride	decreases expression, increases abundance	2
Particulate Matter	decreases expression, increases abundance	2
methylmercuric chloride	decreases expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
cobaltous chloride	decreases expression	1
aflatoxin B2	increases methylation	1
1-nitropyrene	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
dinophysistoxin 1	decreases expression	1
perfluorooctane sulfonic acid	increases expression	1
entinostat	increases expression	1
K 7174	decreases expression	1
abrine	decreases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, decreases expression	1
jinfukang	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Zoledronic Acid	increases expression	1
Amiodarone	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01169220	PHASE4	COMPLETED	Bowel Preparation for Inpatient Colonoscopy
NCT01170754	PHASE4	COMPLETED	Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy
NCT02052557	PHASE4	COMPLETED	The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery
NCT02078726	PHASE4	COMPLETED	Glucagon Use in Colonoscopies
NCT02231203	PHASE4	COMPLETED	Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function
NCT02314871	PHASE4	COMPLETED	Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery
NCT02746432	PHASE4	UNKNOWN	Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial
NCT02887365	PHASE4	UNKNOWN	A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer
NCT02937506	PHASE4	COMPLETED	Patient Satisfaction With Propofol for Out Patient Colonoscopy
NCT02958566	PHASE4	UNKNOWN	Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery
NCT04269369	PHASE4	UNKNOWN	Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients
NCT04311099	PHASE4	COMPLETED	Optimal Peripheral Nerve Block After Minimally Invasive Colon Surgery
NCT04709770	PHASE4	UNKNOWN	Low-volume vs High-volume Polyethylene Glycol Based Bowel Preparation for Colonoscopy in People Receiving Hemodialysis
NCT05250648	PHASE4	RECRUITING	Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)
NCT00002968	PHASE3	COMPLETED	Edrecolomab in Treating Patients With Stage II Colon Cancer
NCT00003835	PHASE3	COMPLETED	Combination Chemotherapy in Treating Patients With Stage III Colon Cancer
NCT00003873	PHASE3	COMPLETED	Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer
NCT00004931	PHASE3	COMPLETED	Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer
NCT00005036	PHASE3	COMPLETED	Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
NCT00005094	PHASE3	COMPLETED	Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps
NCT00025337	PHASE3	COMPLETED	Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
NCT00070122	PHASE3	TERMINATED	Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
NCT00079274	PHASE3	COMPLETED	Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
NCT00096278	PHASE3	COMPLETED	Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
NCT00188305	PHASE3	COMPLETED	A Randomized Trial of Cancer Risk and Health Education in Relatives of Colorectal Cancer Patients
NCT00195585	PHASE3	COMPLETED	Study Evaluating Isovorin in Colon Cancer
NCT00217737	PHASE3	ACTIVE_NOT_RECRUITING	Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
NCT00230646	PHASE3	COMPLETED	Promoting Physical Activity After Colorectal Cancer
NCT00309530	PHASE3	COMPLETED	Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C
NCT00309543	PHASE3	COMPLETED	Randomized Trial on Adjuvant Chemotherapy in Colon Carcinoma Dukes B
NCT00337389	PHASE3	UNKNOWN	Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.
NCT00467922	PHASE3	COMPLETED	An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy
NCT00499369	PHASE3	TERMINATED	Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
NCT00509444	PHASE3	COMPLETED	Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial
NCT00646607	PHASE3	COMPLETED	FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer
NCT00687830	PHASE3	COMPLETED	Efficacy of Morning-only Bowel Preparation for Afternoon Colonoscopy.
NCT00756548	PHASE3	COMPLETED	BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
NCT00756977	PHASE3	COMPLETED	BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
NCT00894725	PHASE3	COMPLETED	Laparoscopic Versus Open Left Colonic Resection
NCT00911170	PHASE3	COMPLETED	PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study